No abstract

No abstract

No abstract

No abstract

This study shows that from the viewpoint of the German pharmaceutical industry the French and Italian markets require an unusual corporate international strategy. Foreign subsidiaries export bulk chemicals and semi‐processed drugs. Regulation favouring direct foreign investment results in foreign affiliates carrying out nearly the same range of activities as their parent companies. Entry into these markets is thus deterred. Some conclusions are drawn on the consequences of such international competitive restrictions as they effect the market performance of international competitive processes.